Annovis Bio Files 8-K on Financials
Ticker: ANVS · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations
TL;DR
Annovis Bio dropped an 8-K on Nov 13th covering financials and operations as of Nov 12th.
AI Summary
Annovis Bio, Inc. filed an 8-K on November 13, 2025, reporting events as of November 12, 2025. The filing pertains to Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The company, formerly known as QR Pharma, Inc., is incorporated in Delaware and headquartered in Malvern, PA.
Why It Matters
This 8-K filing provides an update on Annovis Bio's operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial and operational information, not indicating any immediate significant risks or events.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- QR Pharma, Inc. (company) — Former Company Name
- November 12, 2025 (date) — Date of earliest event reported
- November 13, 2025 (date) — Filing Date
- Malvern, PA (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates that it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details are not provided in the header information.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 12, 2025.
What is the principal executive office address for Annovis Bio, Inc.?
The principal executive offices are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
Has Annovis Bio, Inc. changed its name previously?
Yes, Annovis Bio, Inc. was formerly known as QR Pharma, Inc., with a date of name change on December 2, 2009.
What is the SIC code for Annovis Bio, Inc.?
The Standard Industrial Classification (SIC) code for Annovis Bio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2025-11-12 17:49:26
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ANVS New York Stock Exch
Filing Documents
- anvs-20251112x8k.htm (8-K) — 36KB
- anvs-20251112xex99.htm (EX-99) — 146KB
- 0001104659-25-110548.txt ( ) — 304KB
- anvs-20251112.xsd (EX-101.SCH) — 3KB
- anvs-20251112_lab.xml (EX-101.LAB) — 16KB
- anvs-20251112_pre.xml (EX-101.PRE) — 10KB
- anvs-20251112x8k_htm.xml (XML) — 5KB
02
Item 2.02 Results of Operations and Financial Condition. On November 12, 2025, Annovis Bio, Inc. (the "Registrant") issued a press release reporting earnings for the quarter and nine months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99 Press Release dated November 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: November 12, 2025 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer